参考文献/References:
[1] Van BL,Scherer H,Froehlich A,et al.Une deuxieme observation de cholesterinose tendineuse symetrique avec symptomes cerebraux[J].Ann Med,1937,42:69-101.
[2] Cali JJ,Russell DW.Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis[J].J Biol Chem,1991,266(12):7774-7778.
[3] Cali JJ,Hsieh CL,Francke U,et al.Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis[J].Journal of Biological Chemistry,1991,266(12):7779-7783.
[4] Gascon-Barré M,Demers C,Ghrab O,et al.Expression of CYP27A, a gene encoding a vitamin D-25 hydroxylase in human liver and kidney[J].Clin Endocrinol(Oxf),2001,54(1):107-115.
[5] Verrips A,Hoefsloot LH,Steenbergen GC,et al.Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis[J].Brain,2000,123( Pt 5):908-919.
[6] Björkhem I.Hansson M.Cerebrotendinous xanthomatosis:an inborn error in bile acid synthesis with defined mutations but still a challenge[J].Biochem Biophys Res Commun,2010,396(1):46-49.
[7] Björkhem I,Skrede S,Buchmann MS,et al.Accumulation of 7α-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: effect of treatment with chenodeoxycholic acid[J].Hepatology,1987,7(2):266-271.
[8] Panzenboeck U,Andersson U,Hansson M,et al.On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis[J].J Lipid Res,2007,48(5):1167-1174.
[9] Moghadasian MH.Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds[J].Clin Invest Med,2004,27(1):42-50.
[10] Nie SK,Chen GQ,Cao XB,et al.Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management[J].Orphanet J Rare Dis,2014,9:179.
[11] Lorincz MT,Rainier S,Thomas D,et al.Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized[J].Arch Neurol,2005,62(9):1459-1463.
[12] Verrips A,Van EB,Wevers RA,et al.Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis[J].Arch Neurol,2000,57(4):520.
[13] DeBarber AE,Luo J,Star-Weinstock M,et al.A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns[J].J Lipid Res,2014,55(1):146-154.
[14] Yahalom G,Tsabari R,Molshatzki N,et al.Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis[J].Clin Neuropharmacol,2013,36(3):78-83.
[15] Stelten BML,Huidekoper HH,van de Warrenburg BPC,et al.Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start[J].Neurology,2019,92(2):e83-e95.
[16] Federico A,Dotti MT.Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy[J].J Child Neurol,2003,18(9):633-638.
[17] 叶博闻,王凌椿,戴号.脊髓型脑腱黄瘤病一例[J].中国临床案例成果数据库,2022,04(01):E02454-E02454.
[18] Höflinger P,Hauser S,Theurer Y,et al.Induced pluripotent stem cells(iPSCs)derived from cerebrotendinous xanthomatosis(CTX)patient's fibroblasts carrying a R395S mutation[J].Stem Cell Res,2016,17(2):433-436.
[19] Tao QQ,Zhang Y,Lin HX,et al.Clinical and genetic characteristics of Chinese patients with cerebrotendinous xanthomatosis[J].Orphanet J Rare Dis,2019,14(1):282.
[20] Tibrewal S,Duell PB,DeBarber AE,et al.Cerebrotendinous xanthomatosis:early diagnosis on the basis of juvenile cataracts[J].Journal of American Association for Pediatric Ophthalmology and Strabismus,2017,21(6):505-507.
[21] Pilo-de-la-Fuente B,Jimenez-Escrig A,Lorenzo JR,et al.Cerebrotendinous xanthomatosis in Spain:clinical,prognostic,and genetic survey:cerebrotendinous xanthomatosis in Spain[J].European Journal of Neurology,2011,18(10):1331-1468.
[22] Mondelli M,Sicurelli F,Scarpini C,et al.Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study[J].J Neurol Sci,2001,190(1/2):29-33.
[23] Hollak CEM.Expanding the clinical spectrum of cerebrotendinous xanthomatosis: implications for newborn screening, follow-up and treatment[J].J Intern Med,2021,290(5):942-943.
[24] Salen G.Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism[J].Ann Intern Med,1971,75(6):843-851.
[25] Schotsmans K,De Cauwer H,Baets J,et al.Cerebrotendinous xanthomatosis presenting with asymmetric parkinsonism: a case with I-123-FP-CIT SPECT imaging[J].Acta Neurol Belg,2012,112(3):287-289.
[26] Verrips A.Spinal xanthomatosis:a variant of cerebrotendinous xanthomatosis[J].Brain,1999,122(8):1589-1595.
[27] Argov Z,Soffer D,Eisenberg S,et al.Chronic demyelinating peripheral neuropathy in cerebrotendinous xanthomatosis[J].Ann Neurol,1986,20(1):89-91.
[28] Zhang S,Li W,Zheng R,et al.Cerebrotendinous xanthomatosis with peripheral neuropathy: a clinical and neurophysiological study in Chinese population[J].Ann Transl Med,2020,8(21):1372.
[29] 王帅帅,周爱红,纪艾玲,等.脑腱黄瘤病的临床特征分析[J].中华神经医学杂志,2019,18(9):4.
[30] Kuwabara K,Hitoshi S,Nukina N,et al.PET analysis of a case of cerebrotendinous xanthomatosis presenting hemiparkinsonism[J].J Neurol Sci,1996,138(1/2):145-149.
[31] Su CS,Chang WN,Huang SH,et al.Cerebrotendinous xanthomatosis patients with and without parkinsonism:clinical characteristics and neuroimaging findings:neuroimages in CTX with/without Parkinsonism[J].Mov Disord,2010,25(4):452-458.
[32] Menkes JH,Schimschock JR,Swanson PD.Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system[J].Arch Neurol,1968,19(1):47-53.
[33] Nicholls Z,Hobson E,Martindale J,et al.Diagnosis of spinal xanthomatosis by next-generation sequencing: identifying a rare, treatable mimic of hereditary spastic paraparesis[J].Pract Neurol,2015,15(4):280-283.
[34] Stelten BML,Lycklama À Nijeholt GJ,Hendriks E,et al.Long-term MRI findings in patients with cerebrotendinous xanthomatosis treated with chenodeoxycholic acid[J].Neurology,2022,99(13):559-566.
[35] Pedley TA,Emerson RG,Warner CL,et al.Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid[J].Ann Neurol,1985,18(4):517-518.
[36] Kuriyama M,Tokimura Y,Fujiyama J,et al.Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use[J].J Neurol Sci,1994,125(1):22-28.
[37] Nakamura T,Matsuzawa Y,Takemura K,et al.Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis[J].Metabolism,1991,40(7):741-746.
[38] Verrips A,Wevers RA,Van Engelen BGM,et al.Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis[J].Metabolism,1999,48(2):233-238.